{"id":"basiliximab-tacrolimus-mmf","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Neurotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1201439","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basiliximab is a chimeric monoclonal antibody that blocks the IL-2 receptor on T cells, preventing their activation. Tacrolimus is a calcineurin inhibitor that suppresses T-cell cytokine production. Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase, selectively suppressing lymphocyte proliferation. Together, these agents provide multi-target immunosuppression to prevent allograft rejection.","oneSentence":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:10.929Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in solid organ transplant recipients"}]},"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT01780844","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-03-05","conditions":"Kidney Transplantation","enrollment":149},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT02342145","phase":"PHASE4","title":"Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major","status":"COMPLETED","sponsor":"Zhongming Zhang","startDate":"2015-04","conditions":"Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)","enrollment":205},{"nctId":"NCT03478215","phase":"PHASE2","title":"Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2016-12","conditions":"Renal Transplantation, Mesenchymal Stem Cells","enrollment":24},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT00717470","phase":"PHASE4","title":"A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05-14","conditions":"Kidney Transplantation","enrollment":1252},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01304836","phase":"PHASE4","title":"A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-22","conditions":"Kidney Transplantation","enrollment":1166},{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT03794492","phase":"PHASE4","title":"Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-03-31","conditions":"Kidney Transplant","enrollment":169},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT05385432","phase":"PHASE3","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-09-12","conditions":"Renal Transplant Rejection, Induction Therapy","enrollment":244},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":"Uterus Transplant","enrollment":""},{"nctId":"NCT02123108","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-01","conditions":"Liver Transplantation","enrollment":59},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT00492869","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":124},{"nctId":"NCT00403416","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Kidney Transplantation","enrollment":215},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT01387659","phase":"NA","title":"Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2011-03","conditions":"Diabetes, Immunosuppression","enrollment":2},{"nctId":"NCT01136395","phase":"PHASE2","title":"Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2010-01","conditions":"Kidney Transplantation, Rituximab (RTx), Living Donors","enrollment":85},{"nctId":"NCT02723786","phase":"PHASE2","title":"Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-08-27","conditions":"Kidney Transplantation (Status Post)","enrollment":7},{"nctId":"NCT01649427","phase":"PHASE4","title":"Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-17","conditions":"Pharmacokinetics Study in de Novo Kidney Transplantation","enrollment":73},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT03789006","phase":"PHASE4","title":"Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation","status":"UNKNOWN","sponsor":"University of Khartoum","startDate":"2018-03-21","conditions":"Kidney Transplant Rejection","enrollment":300},{"nctId":"NCT01884571","phase":"PHASE2","title":"Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-10","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":31},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00229138","phase":"PHASE4","title":"Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Kidney Transplantation","enrollment":291},{"nctId":"NCT03005236","phase":"PHASE4","title":"AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2017-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT02558452","phase":"","title":"European Transplant Registry of Senior Renal Transplant Recipients on Advagraf","status":"NOT_YET_RECRUITING","sponsor":"Klemens Budde","startDate":"2016-12","conditions":"Graft Failure, Death, Acute Rejection of Renal Transplant","enrollment":1000},{"nctId":"NCT01336296","phase":"PHASE4","title":"Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2010-09","conditions":"Kidney Transplant Recipients","enrollment":61},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT00859131","phase":"NA","title":"Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":"End Stage Renal Disease","enrollment":200},{"nctId":"NCT00468403","phase":"PHASE2","title":"LEA29Y (Belatacept) Emory Edmonton Protocol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT01656135","phase":"PHASE4","title":"Reference Group Trial for The ONE Study","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2012-12","conditions":"End-stage Renal Failure, Kidney Graft Rejection","enrollment":70},{"nctId":"NCT02683291","phase":"PHASE4","title":"Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients","status":"COMPLETED","sponsor":"Associação Médico Espírita de Botucatu","startDate":"2014-01","conditions":"Disorder Related to Renal Transplantation, Cytomegalovirus Infections","enrollment":48},{"nctId":"NCT00543569","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-02","conditions":"Kidney Transplantation","enrollment":323},{"nctId":"NCT02561767","phase":"PHASE1, PHASE2","title":"Effect of BM-MSCs in DCD Kidney Transplantation","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-10","conditions":"Kidney Transplantation, Acute Kidney Tubular Necrosis","enrollment":120},{"nctId":"NCT01354301","phase":"PHASE4","title":"Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2011-05","conditions":"Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection","enrollment":300},{"nctId":"NCT02328222","phase":"PHASE4","title":"ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION","status":"COMPLETED","sponsor":"Unidad de Investigacion Medica en Enfermedades Renales","startDate":"2010-06","conditions":"END STAGE RENAL DISEASE","enrollment":71},{"nctId":"NCT00724022","phase":"PHASE4","title":"Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2008-06","conditions":"Disorder Related to Renal Transplantation","enrollment":600},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT01435291","phase":"PHASE4","title":"AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-10","conditions":"Renal Transplantation","enrollment":45},{"nctId":"NCT00790439","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Diabetes Mellitus, Type I","enrollment":""},{"nctId":"NCT02095418","phase":"NA","title":"Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2014-02","conditions":"Diabetes","enrollment":152},{"nctId":"NCT00853424","phase":"PHASE3","title":"A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2009-12","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01766518","phase":"PHASE4","title":"The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2009-11","conditions":"Evidence of Liver Transplantation","enrollment":120},{"nctId":"NCT00296244","phase":"PHASE4","title":"Steroid Free Immunosuppression in Liver Transplantation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-02","conditions":"Liver Cirrhosis, Liver Transplant Disorder","enrollment":40},{"nctId":"NCT00555321","phase":"PHASE2","title":"Belatacept in Liver Transplant Recipients","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-01","conditions":"Immunosuppression in Solid Organ Transplant","enrollment":260},{"nctId":"NCT01550445","phase":"PHASE4","title":"Steroid Withdrawal Immunosuppression After Renal Transplantation","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2008-05","conditions":"Disorder Related to Renal Transplantation","enrollment":30},{"nctId":"NCT00610961","phase":"","title":"Induction Related BK Viremia in Renal Transplant Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2007-10","conditions":"Disease Due to BK Polyomavirus, Transplantation Infection, Disorder Related to Transplantation","enrollment":60},{"nctId":"NCT00113269","phase":"PHASE4","title":"Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-05","conditions":"Kidney Transplantation","enrollment":501}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Simulect","Advagraf","CellCept"],"phase":"marketed","status":"active","brandName":"Basiliximab, Tacrolimus, MMF","genericName":"Basiliximab, Tacrolimus, MMF","companyName":"University Hospital Freiburg","companyId":"university-hospital-freiburg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of acute organ rejection in solid organ transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}